Fundraising Fox
Chicago · Pre-Seed–Series A
Find your way into Portal Innovations
Sign up to see every warm intro you have to Portal Innovations
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Portal Innovations team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Portal Innovations backs science-driven, life science and biotech entrepreneurs through what it calls 'Crafted Capital' — a combination of human, financial, and physical resources. It provides seed funding, world-class wet/dry lab and office space in emerging work/live/play ecosystems, and connections to a broad network of investors, partners, and management and science leaders. Operating a national membership model with lab locations across multiple U.S. cities, the firm surrounds entrepreneurs with the resources and community needed to advance biomedical and med tech innovation and grow their startups where they live.
Source: firm website, verified Sep 25, 2026.
Founder mafia
2 people who came through Portal Innovations went on to found or lead other companies.
What they invest in
from 27 of 31 portfolio companiesBiotech ×24Healthtech ×12Medical Devices ×12Deep Tech ×10AI & Machine Learning ×7Digital Health ×4Longevity ×3Hardware ×1
HQs:United States×18
Who they back
founder profiles across 17 portfolio companiesFounding team size:solo founder×42 founders×53 founders×44+ founders×4
Where their founders studiedfrom 20 founders with education data
Georgia Institute of Technology ×2Northwestern University ×2University of California, Berkeley ×2University of Chicago ×2University of Illinois College of Medicine ×2University of Wisconsin-Madison ×2
What their founders studiedfrom 20 founders with field-of-study data
Life Sciences ×8Engineering ×7Chemistry ×2
Where their founders worked beforefrom 21 founders with career history
Massachusetts Institute of Technology (MIT) ×3ALZA Corporation ×2Georgia Institute of Technology ×2Harvard Medical School ×2Massachusetts General Hospital ×2Sana Biotechnology ×2
15 founders hold a PhD · 5 hold an MBA (of 21 with degree data)
Investments · 31 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 32023 · 12022 · 38 dated
Arase Therapeutics develops first-in-class oncology therapeutics that target ADP-ribose Hydrolases, novel proteins in cancer stress pathways.
BiotechMedical Devices
Paul Chang(President, CEO / CSO and Lead Founder)inW. Lee Kraus(Scientific Founder)Michael Taylor(Executive Chairman)in
Co-investorsMission Biocapital
Cardiosense develops wearable sensing hardware and deep-learning algorithms that convert physiological signals into clinical insights for cardiovascular disease detection and management.
AI & Machine LearningDigital HealthHealthtechMedical DevicesChicago, US
Amit Gupta(Co-founder, Advisor)inMozziyar Etemadi(Co-founder, Head of AI)Omer Inan(Co-founder, Chief Scientific Officer)inAndrew Carek(Co-founder, Chief Technical Officer)inEric Meizlish(Chief Executive Officer)inJohn D. Martin(Chief Medical Officer)in
Co-investorsBayMed Venture PartnersBroadview VenturesCross-Border Impact VenturesLaerdal Million Lives FundOSF VenturesArboretum Ventures+1 more
CiRC Biosciences develops cellular reprogramming therapies that convert fibroblasts directly into specific neurons and cell types lost in degenerative eye and brain diseases.
BiotechDeep TechMedical DevicesChicago, US
Darien Parhad(Executive Officer)Patrick Morris(Executive Officer, Director)Sai Chavala(Director)
BoardTimothy Cunniff(Director)Antonio Gracias(Director)inJeffrey Aronin(Director)
Co-investorsParagon Biosciences LLCValor Equity Partners
ClostraBio develops next-generation probiotics and a platform for delivering bacterial metabolites to support gut health, targeting inflammatory bowel disease (IBD) and food allergy.
BiotechDigital HealthHealthtechChicago, US
Jeffrey Hubbell(Secretary)Cathryn Nagler(President)inBrett Newswanger(Chief Operating Officer)
BoardJohn Flavin(Executive Chairman)in
Co-investorsStone Mountain Ventures
CrossBridge Bio, launched in 2023, develops next-generation antibody-drug conjugates (ADCs) to address a range of cancer indications.
BiotechHealthtechHouston, US
Kyoji Tsuchikama(Executive Officer, Director, Promoter)Michael Torres(Executive Officer, Director, Promoter)
BoardWilliam F. McKeon(Director)Damir Illich(Director)Patrick James Crutcher(Director)
Co-investorsTMC Venture FundPortal
Dimension Bio is a biotechnology company developing regenerative therapeutics using its BioNidum platform, which combines materials science, 3D printing, and digital manufacturing to produce implantable and injectable biosynthetic scaffolds that promote tissue healing.
BiotechHealthtechMedical DevicesNew MaterialsChicago, US
Caralynn Nowinski Collens(Co-founder & CEO)inRamille Shah, Ph.D.(Co-founder & CSO)Ramille Shah(Co-founder & CSO)Adam Jakus(Co-Founder)inLarry Weinstein(SVP, Manufacturing & Quality Operations)Cole Johnson(SVP, Corporate Development)in
Co-investorsAlumni VenturesBetter Ventures Central LlcHarvard Business Angels of ChicagoHAWKTAILLofty VenturesPathway Bioventures+4 more
.png)
Grove Biopharma develops Bionic Biologics, a drug discovery platform combining AI-enabled molecular design, precision polymer chemistry, and experimental biology to target protein-protein interactions that are inaccessible to conventional therapeutics.
AI & Machine LearningBiotechDeep TechChicago, US
Geoffrey Duyk(CEO)in
Co-investorsDCVC (Data Collective)DCVC BioInVivium CapitalDeepWork Capital
Inomagen Therapeutics develops a non-viral gene therapy delivered via a single-dose, minimally invasive procedure to target the underlying mechanisms of atrial fibrillation.
BiotechHealthtechMedical DevicesChicago, US
Rishi Arora(Founder)Gerard Abate(Chief Medical Officer)Eric Sandberg(Chief Business Officer)in
BoardMarc Penn(Director)James R. Vogler(Director)
Iterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway.
BiotechHealthtech
Rahul Aras(Chief Executive Officer)inOvid Trifan(Chief Medical Officer)inSteve Horrigan(Chief Scientific Officer)in
Co-investorsGreen Park & Golf VenturesLumira Ventures
March Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments.
BiotechMedical DevicesHouston, US
Sarah Hein(CEO, Co-Founder)inMaksim Mamonkin(Co-Founder, Chair Scientific Advisory Board)Malcolm Brenner(Co-founder)
BoardThomas Luby(Director)inPeter Olagunju(Director)inJoseph Petrosino(Director)
Co-investorsMission Biocapital4BIO CapitalCancer FocusCancer FundFitz Gate VenturesModi Ventures+2 more
Moonlight Therapeutics is a clinical-stage biotech company developing an intradermal stamp-based immunotherapy for people with food allergies.
BiotechHealthtech
Co-investorsAllerfund Ventures, Llc
NovaScan develops a platform technology combining AI and spectral bioimpedance for oncology applications, with multiple diagnostic and intraoperative products built on a shared hardware and software foundation currently in clinical trials.
AI & Machine LearningHealthtechMedical Devices
Co-investorsDipalo VenturesGreen Park & Golf VenturesHarvard Business Angels of Chicago
Pelagos Pharma develops drugs targeting hard-to-treat receptors for age-related diseases, with a focus on extending healthspan and longevity.
BiotechDeep TechHealthtechLongevity
Reaxbio develops a chemoproteomics platform that identifies and targets novel protein sites for drug discovery across disease-relevant biological contexts.
AI & Machine LearningBiotechDeep Tech
Jeff Montgomery(Founder)in
Co-investorsOMX Ventures
Rhaeos develops FlowSense, a noninvasive wireless wearable skin patch that monitors fluid flow in the body, initially targeting hydrocephalus patients who depend on implantable shunts for cerebrospinal fluid management.
HardwareHealthtechMedical DevicesEvanston, US
Dr. Chad WebbJohn A. Rogers(Executive Officer, Director)Roozbeh Ghaffari(Director)inAnna Lisa Somera(Executive Officer)inChad Seaver(Director)R. Chad Webb(Executive Officer, Director)
Co-investorsCreative VenturesSteele Foundation for HopeLateral Capital
RNAV8 Bio develops a toolkit for engineering mRNA therapeutics, optimizing non-coding sequences to improve expression and efficacy of mRNA-based treatments.
AI & Machine LearningBiotechLaguna Niguel, US
Devan ShahinMichelle Lynn Hall
Co-investorsBioBritElmehøj VenturesService Provider Capital
Synaptrix develops NOVABLOC, a non-opioid neuromodulation therapy that uses electrical stimulation to provide targeted, long-lasting postoperative pain relief.
BiotechDigital HealthMedical DevicesAlpharetta, US
Shyamy Sastry(Executive Officer, Director)
BoardDoug Reed(Director)Robert Crutchfield(Executive Officer, Director)Anita Watkins(Director)inKurt Jacobus(Director)in
Co-investorsHatteras Venture Partners
Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation.
BiotechDeep TechMedical DevicesChicago, US
Ryan Clarke(Co-Founder, Chief Scientific Officer)inNiko Balanis, PhD(Co-Founder, Chief Technology Officer)inBrad Merrill, PhD(Co-Founder, Head of Innovation)Matt MacDougall, MD, PhD(Scientific Cofounder, Immunology Physician, Stanford University)inPatrick Shaddow(Executive Officer, Director)John Craighead, PhD(Chief Executive Officer)
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)DCVC BioDraper AssociatesIllumina VenturesWalder Ventures
Syntis Bio develops oral therapies that use the biology of the small intestine to treat conditions ranging from rare genetic disorders to common diseases.
BiotechDeep TechDigital HealthHealthtechBoston, US
Rahul Dhanda(Executive Officer, Director)inCarlo Giovanni Traverso(Director)Robert Langer(Director)
BoardTeymour Boutros-Ghali(Director)inMartin Madaus(Director)
Co-investorsBill & Melinda Gates FoundationBold Capital PartnersCerity Partners VenturesColorcon VenturesSafar PartnersSky9 Capital
Transcera is a biotech company developing a new class of therapeutics that use lipid trafficking pathways to direct extracellular proteins into lysosomes for degradation, aimed at treating chronic diseases.
BiotechDeep TechBoston, US
Wayne Lencer(Founder)Hunter Goble(Founder)inJustin Wolfe(Founder)inWilliam Hunter Goble(Executive Officer, Director)Phil Grayeski(Director)
Co-investorsPear VCTau VenturesDigitalis VenturesKdT VenturesTAU VenturesXora Innovation Pte Ltd
Vincere Biosciences develops small-molecule therapeutics targeting mitochondrial quality control and mitophagy, primarily for neurodegenerative diseases including Parkinson's disease.
AI & Machine LearningBiotechDeep TechLongevity
Co-investorsAlumni VenturesBeiersdorf Innovation FundBeresford VenturesDraper AssociatesFreemind InvestmentsquadraScope Venture Fund
Vivtex is a drug development company applying computational science and pre-clinical research to advance new medicines.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
Thomas von Erlach(CEO & Co-founder)inRobert Langer(Co-founder)Giovanni Traverso(Co-founder)inJAMES WINSCHEL(Executive Officer, Director)JUAN LOPEZ(Executive Officer)JACQUES BARBUT(Director)
Walder Ventures is a mission-driven investment vehicle established by Joseph and Elizabeth Walder to support programs and organizations benefiting the Chicago region, with a focus on life sciences and sustainability.
BiotechImpact & Social GoodChicago, US
Joseph Walder(Co-founder)Elizabeth Walder(Co-founder & President)
Zylem Biosciences develops Metabolic Redox Modulators (MRMs), a patented platform of drug candidates targeting the SR-B1 receptor to treat cancer, cardiovascular disease, and other age-related conditions.
BiotechLongevityMedical Devices
Shad Thaxton(MD, PhD)Kaylin McMahon(PhD)Philip Bligh
BoardJay Venkatesan(MD, MBA)Leo Gordon(MD)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Alnair TherapeuticscTRL TherapeuticsMoonlight TherapeuticsRNAv8TopoDxVasarya
Portfolio news
latest coverage across their companies
Rnav8 BIO · prweb.com · Sep 1, 2026
Vivtex · biospace.com · Feb 25, 2026
Syntis Bio · finsmes.com · Jul 1, 2025
Frequently asked questions
- How many investments has Portal Innovations made?
- Portal Innovations has 31 tracked investments, including 3 dated in the last 24 months.
- What stage does Portal Innovations invest at?
- Portal Innovations invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Portal Innovations focus on?
- Portal Innovations focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- Where is Portal Innovations located?
- Portal Innovations is headquartered in Chicago, US.
- Who does Portal Innovations co-invest with?
- Portal Innovations most often shares deals with DCVC Bio, DCVC (Data Collective), Draper Associates, among 52 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.